Young Oh Kweon

Young Oh Kweon

Auto-generated profile, based on publicly available information

Young Oh Kweon

Department of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
LMLung-Yi Loey Mak
Lung-Yi Loey Mak
EGEd Gane
Ed Gane
CSChristian Schwabe
Christian Schwabe
KYKi Tae Yoon
Ki Tae Yoon
JHJeong Heo
Jeong Heo
MYMan-Fung Yuen
Man-Fung Yuen

26 May 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
HLHan Ah Lee
Han Ah Lee
HLHYUN WOONG LEE
HYUN WOONG LEE
IKIn-Hee Kim
In-Hee Kim
JPJun Yong Park
Jun Yong Park
DSDong Hyun Sinn
Dong Hyun Sinn
Seung Up KimSeung Up Kim
Seung Up Kim
Summary: Background: Anti‐viral therapy is not indicated for patients with chronic hepatitis B (CHB) in the immune‐tolerant phase.Aims: To investigate the cumulative incidence of phase change and hepatocellular carcinoma (HCC) and independent predictors for phase change in patients with CHB in immune‐tolerant phase.Methods: In total, 946 patients in immune‐tolerant phase, defined as hepatitis B e antigen positivity, HBV‐DNA >20 000 IU/mL and alanine aminotransferase (ALT) ≤40 IU/L, between 1989 and 2017 were enrolled from eight institutes.Results: The mean age of study population (429 men and 517 women) was 36.7 years. The mean ALT and HBV‐DNA levels were 24.6 IU/L and 8.50 log10 IU/mL, respectively. Of the study population, 476 (50.3%) patients remained in immune‐tolerant phase throughout the study period (median: 63.6 months). The cumulative incidence rates of phase change and HCC at 10 years were 70.7% and 1.7%, respectively. Multivariate analyses revealed that HBV‐DNA level >107 IU/mL was associated independently with a reduced risk of phase change (hazard ratio [HR] = 0.734, P = 0.008), whereas a high ALT level, above the cut‐off recommended in the Korean Association for the Study of the Liver guidelines (34 IU/L for men and 30 IU/L for women), was associated independently with a greater risk of phase change (HR = 1.885, P < 0.001).Conclusions: The criterion of HBV‐DNA level > 107 IU/mL may be useful to define immune‐tolerant phase. In addition, an extremely low risk of HCC development was observed in patients with CHB in immune‐tolerant phase.

15 May 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
JPJung Gil Park
Jung Gil Park
WTWon Young Tak
Won Young Tak
JPJun Yong Park
Jun Yong Park
YKYoung Oh Kweon
Young Oh Kweon
WCWoo Jin Chung
Woo Jin Chung
WLWon Kee Lee
Won Kee Lee
Background and Aims: Clinical evidence for the benefits of branched-chain amino acids (BCAAs) is lacking in advanced liver disease. We evaluated the potential benefits of long-term oral BCAA supplementation in patients with advanced liver disease. Methods: Liver cirrhosis patients with Child–Pugh (CP) scores from 8 to 10 were prospectively recruited from 13 medical centers. Patients supplemented with 12.45 g of daily BCAA granules over 6 months, and patients consuming a regular diet were assigned to the BCAA and control groups, respectively. The effects of BCAA supplementation were evaluated using the model for end-stage liver disease (MELD) score, CP score, serum albumin, serum bilirubin, incidence of cirrhosis-related events, and event-free survival for 24 months. Results: A total of 124 patients was analyzed: 63 in the BCAA group and 61 in the control group. The MELD score (p = 0.009) and CP score (p = 0.011) significantly improved in the BCAA group compared to the control group over time. However, the levels of serum albumin and bilirubin in the BCAA group did not improve during the study period. The cumulative event-free survival was significantly improved in the BCAA group compared to the control group (HR = 0.389, 95% CI = 0.221–0.684, p < 0.001). Conclusion: Long-term supplementation with oral BCAAs can potentially improve liver function and reduce major complications of cirrhosis in patients with advanced liver disease.

13 May 2020 in Genes
Verified
Journal Article
Open access
PDF file
MHMan-Hoon Han
Man-Hoon Han
JLJee Hyun Lee
Jee Hyun Lee
GKGyeonghwa Kim
Gyeonghwa Kim
ELEunhye Lee
Eunhye Lee
YLYu Rim Lee
Yu Rim Lee
Keun HurKeun Hur
Keun Hur
Background: Advanced liver fibrosis is the most important prognostic factor in nonalcoholic fatty liver disease (NAFLD). The long noncoding RNA (lncRNA), growth arrest-specific transcript 5 (GAS5), is associated with the inhibition of liver fibrogenesis, and its levels are decreased in cirrhotic liver. Methods: We analyzed 51 patients with NAFLD, the diagnosis of which was confirmed by liver biopsy. Expression of GAS5 in both the liver and plasma of the patients was analyzed using a quantitative real-time polymerase chain reaction according to the fibrosis stage. Results: Plasma GAS5 expression was significantly higher in patients with advanced fibrosis than in those without. As the fibrosis progressed, GAS5 expression in plasma increased, with the exception of that in cirrhotic livers. Plasma levels of GAS5 were lower in patients with cirrhosis than in those with advanced fibrosis. Conclusion: Elevated circulating levels of the lncRNA GAS5 are associated with the progression of liver fibrosis prior to the development of cirrhosis.

1 May 2021 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
SJSe Young Jang
Se Young Jang
WTWon Young Tak
Won Young Tak
JPJun Yong Park
Jun Yong Park
YKYoung-Oh Kweon
Young-Oh Kweon
YLYu Rim Lee
Yu Rim Lee
PHPh.D.
Ph.D.
Se Young Jang, M.D., Won Young Tak, M.D., Soo Young Park, M.D., Young-Oh Kweon, M.D., Yu Rim Lee, M.D., Gyeonghwa Kim, Ph.D., Keun Hur, Ph.D., Man-Hoon Han, M.D., and Won Kee Lee, Ph.D.. Ann Lab Med 2021;41:302-9. https://doi.org/10.3343/alm.2021.41.3.302

27 August 2009 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
WTWon Young Tak
Won Young Tak
SPSoo Young Park
Soo Young Park
MJMin Kyu Jung
Min Kyu Jung
SJSeong Woo Jeon
Seong Woo Jeon
CCChang Min Cho
Chang Min Cho
YCYong Hwan Choi
Yong Hwan Choi